Trial Profile
Non-interventional Study to Assess the Safety Profile of Idelalisib in Patients With Refractory Follicular Lymphoma (FL)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Jan 2022
Price :
$35
*
At a glance
- Drugs Idelalisib (Primary)
- Indications Follicular lymphoma
- Focus Adverse reactions
- Acronyms ZEUS
- Sponsors Gilead Sciences
- 14 Dec 2021 Results assessing effectiveness and updated safety analysis from this study, presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 16 Nov 2021 Status changed from active, no longer recruiting to completed.
- 12 Jul 2021 Status changed from recruiting to active, no longer recruiting.